The technique matters just as much as the product choice, especially when dealing with different areas of the body and varying skin types
Essential Preventive Measures: Schedule comprehensive baseline eye examinations before starting GLP-1 therapy to establish documented visual function parameters Maintain routine ophthalmological appointments at intervals recommended by healthcare providers, typically every six to twelve months Report any sudden changes in vision, including blurred vision, dark spots, or peripheral vision loss, immediately to medical professionals Document Everything: Document all visual symptoms with specific details regarding onset, duration, and severity for accurate medical assessment Optic Nerve Heath: Request specific screening for optic nerve health and evaluation of risk factors associated with NAION Pre-existing Conditions: If you have existing conditions such as diabetes, hypertension, or cardiovascular disease, youll need closer monitoring because these conditions increase the risk of optic nerve damage
Key points Cleanse first so the skin is ready for serum
Why Choose Peptides at Huemn
Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space
